MarketInOut Stock Screener Log In | Sign Up
 

Nuvation Bio Inc

NYSE • Healthcare • Biotechnology • Quote as of 10/23/2026
Nuvation Bio Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization1,590.59 mln
Float252 mln
Earnings Date11/04/2026

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

5.8
Highly suspicious

1-Year Forecast

13.00
Transformational upside

Relative Strength

13 / 100
Significantly lagging

Debt / Equity

1.64
High leverage

Pre-Tax Margin

-88%
Severely loss-making

Business Description

Nuvation Bio is a New York-based company focused on finding new treatments for cancer. Its first approved drug, IBTROZI, targets a specific genetic mutation found in certain lung cancer patients. The company is also running late-stage trials for a second drug aimed at treating a form of brain tumor driven by a particular genetic abnormality. Founded in 2018, Nuvation Bio continues to build its pipeline of precision cancer therapies.

Key Fundamentals

EPS-0.44
ROE-47.48
RPS0.50
ROIC-276
ROA-23.42
Interest Cover-5.16
EBITDA, mln-121
EV / EBITDA-14.59
EV / EBIT-14.33
Revenue, mln170
EV / Revenue10.39

Quote Details

Last 4.57
Change -0.13 (-2.77%)
Open 4.62
Volume 3,188,399
Turnover 14,570,984
Average Volume 5,570,883

Financial Ratios

Pre-Tax Profit Margin-88
Leverage Ratio2.93
Current Ratio8.37
Price / Book7.84
Price / Tangible Book8.18
Debt / Equity1.64
Price / Sales12.14

Financial Strength

Altman Z-Score0.93
Piotroski F-Score 4 / 9
Beneish M-Score5.8
1-Year Target Price13.00
Short Ratio12.54
Short % of Float27.61

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 2.7% 84 / 100   
1 Month -20.24% 6 / 100   
2 Months -27% 7 / 100   
6 Months -6.54% 28 / 100   
1 Year 10.12% 57 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog